Delineation of prognostic biomarkers in prostate cancer

By S. Dhanasekaran, T. Barrette, Debashis Ghosh, R. Shah, S. Varambally, K. Kurachi, K. Pienta, Mark A. Rubin, Arul M. Chinnaiyan. Nature, 2001

1,750 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/69d69096ae43de9acd400a5d542a39cb3d62f7bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. E. Koivunen
2. M. Luisa Iruela-Arispe
3. M. Björklund
4. Charles M. Perou
5. C. Sawyers
6. Eric S. Lander
7. E. Scholar
8. A. Arora

In Pathology and Forensic Medicine

1. C. Sawyers

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. John Wongvipat
3. Mark A. Rubin
4. C. Sawyers

Citations in the corpus

• Coexpression analysis of human genes across many microarray data sets. (2004, neutral): “…3409 (Chen et al. 2002) 207 9169 597313 (Ross et al. 2000) 68 5837 45468 (Cheok et al. 2003) 120 8243 258731 (Shipp et al. 2002) 77 5418 87486 (Dhanasekaran et al. 2001) 53 5613 161097 (Singh et al. 2002) 20 4119 19895 (Diehn et al. 2002) 68 10400 1635022 (Smith et al. 2003) 102 8242 248952…”
• ONCOMINE: a cancer microarray database and integrated data-mining platform. (2004, neutral): “potential, and patient survival [1–24].”
• Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. (2004, background): “Overall clinical characteristics of HNSCC patients pression patterns and have shown that these groupings can Age predict clinical outcomes (Alizadeh et al., 2000; Bhattacharjee Median (range) 56 yr (30–77)et al., 2001; Dhanasekaran et al., 2001; Garber et al., 2001; 40 4 (7%)Sorlie et al., 2001).”
• Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. (2002, methodology): “In all four of the published studies, molecular validation was performed on small sets of identified genes (maximum of 4) by Northern blotting (3), reverse transcription-PCR (8–10), in situ hybridization (9), and immunohistochemistry (for protein; Refs.”
• Gelatinase-mediated migration and invasion of cancer cells. (2005, background): “consistently found it to be one of the most upregulated genes in advanced prostate cancer (Dhanasekaran et al., 2001; Magee et al., 2001).”
• Feature Selection via Dependence Maximization (2012, background): “Two deal with prostate cancer (Dhanasekaran et al., 2001; Welsh et al., 2001) (7, 8), two with breast cancer (Gruvberger et al.”